Dexcom G6 Intervention Study

Diabetes Mellitus Clinical Trial

Official title:

Management of Inpatient Hyperglycemia by Continuous Glucose Monitoring in Insulin-treated Patients With Diabetes: Dexcom G6 Intervention Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03877068
• Other study ID #: IRB00107703
• Status: Completed
• Phase: N/A
• Start date: June 26, 2019
• Est. completion date: February 27, 2021

Study information

• Verified date: October 2023
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will assess if Continuous Glucose Monitoring (CGM) represents a better tool to guide healthcare providers in adjusting insulin therapy, by providing a more complete 24-hour assessment of glucose values compared to Point of Care (POC) testing, during hospitalization and after hospital discharge in general medicine and surgery patients with Type 2 Diabetes (T2D) and Type 1 Diabetes (T1D).

Description:

Diabetes is reported in 20-34% of hospitalized adult patients in general medicine and surgery units and there is a large body of literature showing a strong association between diabetes and increased hospital mortality and morbidity. Clinical guidelines have recommended the use of basal bolus insulin regimens as the preferred management approach of non-intensive care unit (ICU) patients with diabetes, as it has been shown to be effective in improving glycemic control and reducing hospital complications. However, hypoglycemia is a common adverse event of insulin therapy, with incidence rates ranging between 12% and 35% in randomized studies in non-ICU settings. The development of hypoglycemia, like hyperglycemia, has been associated with higher rates of hospital complications, higher health care resource utilization, and hospital mortality.

Bedside point-of-care (POC) capillary glucose monitoring is the standard of care to assess glycemic control in the hospital. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital. In contrast to POC testing, continuous glucose monitoring (CGM) measures interstitial glucose every 5-15 minutes, thus providing a more complete glycemic profile during 24-hours compared to standard POC glucose testing. The study will assess if CGM represents a better tool to guide healthcare providers in adjusting insulin therapy by providing a more complete 24-hour assessment of glucose values compared to POC testing, during hospitalization and after hospital discharge in general medicine and surgery patients with T2D and T1D.

Participants will be randomized to have the standard of care POC testing plus wear a sham CGM or to wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days during hospitalization. At the point of hospital discharge, participants with poorly controlled diabetes will be invited to participate in an open label outpatient study where they will wear a Dexcom G6 CGM or sham device for 10 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: February 27, 2021
• Est. primary completion date: February 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females = 18 years admitted to a general medicine or surgical services.

2. History of T1D or T2D receiving insulin therapy during hospital admission.

3. Subjects must have a randomization BG <400 mg/dL without laboratory evidence of diabetic ketoacidosis (bicarbonate < 18 milliequivalents per litre (mEq/L), potential of hydrogen (pH) < 7.30, or positive serum or urinary ketones).

4. Patients with expected hospital length-of-stay of 2 or more day

Exclusion Criteria:

1. Patients with acute illness admitted to the ICU or expected to require admission to the ICU.

2. Patients expected to require MRI procedures during hospitalization.

3. Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, end-stage renal disease (dialysis), or anasarca (massive peripheral edema).

4. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.

5. Female subjects who are pregnant or breast-feeding at time of enrollment into the study.

6. Coronavirus Disease 2019 (COVID-19) infection

Related Conditions & MeSH terms

• Diabetes Mellitus
• Hyperglycemia

Intervention

Device:
• Dexcom G6 CGM - Continues Glucose Monitoring sensor system
A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.

Diagnostic Test:
• POC BG - Point-of-Care Blood Glucose monitoring
Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.

Locations

Country	Name	City	State
United States	Emory University Hospital	Atlanta	Georgia
United States	Grady Health System	Atlanta	Georgia
United States	Univeristy of Maryland	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Daily Blood Glucose (BG) Concentration While Hospitalized	A random (non-fasting) blood glucose measurement of 140 mg/dL or less is considered normal, while a measurement of 200 mg/dL or more indicates diabetes.	During hospitalization (up to 10 days)
Primary	Percent of Time With BG Between 70-180 mg/dL While Hospitalized	Glycemic control is measured by the percent of time with BG in the range of 70-180 mg/dL.	During hospitalization (up to 10 days)
Primary	Number of Clinically Significant Hypoglycemia Events While Hospitalized	The mean number of clinically significant hypoglycemia events, defined as BG <54 mg/dl (3.0mmol/L), per participant is presented here.	During hospitalization (up to 10 days)
Secondary	Number of Hypoglycemia Events While Hospitalized	The mean number of hypoglycemia events, defined as BG < 70 (<3.9 mmol/L), per participant during hospitalization is presented here.	During hospitalization (up to 10 days)
Secondary	Number of Nocturnal Hypoglycemia Events While Hospitalized	The mean number of events of nocturnal hypoglycemia per participant are presented here. Nocturnal hypoglycemia occurs between the hours of 12:00 midnight and 6:00 ante meridiem (AM). Hypoglycemia is defined as BG < 70 mg/dL (<3.9 mmol/L) and severe hypoglycemia is defined as BG < 54 mg/dL (<3.0 mmol/L).	During hospitalization (up to 10 days)
Secondary	Percent of Time With Hypoglycemia While Hospitalized	The percentage of time spent with BG below the desired range, during the day and night of hospitalization was assessed. Hypoglycemia is defined as BG < 70 mg/dL (<3.9 mmol/L) and severe hypoglycemia is defined as BG < 54 mg/dL (<3.0 mmol/L).	During hospitalization (up to 10 days)
Secondary	Percent of Time With Hyperglycemia While Hospitalized	The percentage of time above the desired BG range, during the day and night while hospitalized was assessed.	During hospitalization (up to 10 days)
Secondary	Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) While Hospitalized	Mean amplitude of glycemic excursions (MAGE), together with mean and standard deviation, is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one standard deviation of mean glycemia. It is designed to assess major glucose swings and exclude minor ones.	During hospitalization (up to 10 days)
Secondary	Differences in BG by CGM Devices Placed in the Abdomen and Upper Extremity While Hospitalized	The mean absolute relative difference (MARD) reflects accuracy of the CGM glucose reading compared to the reference POC reading. This is the current standard for assessing accuracy of glucometer readings. Lower MARD indicates smaller differences between the CGM and meter value; a higher MARD value indicates larger differences. A three way and direct head-to-head comparison of data from the abdomen, upper arm and POC BG will be compared.	During hospitalization (up to 10 days)
Secondary	Number of Sensor Changes During Hospitalization	Events related to sensor changes (blinded sensor for the POC group or real-time sensor for CGM group), such as removal for procedures or imaging, sensors failures, and sensors dislodgments were recorded.	During hospitalization (up to 10 days)
Secondary	Mean Daily BG Concentration After Discharge	A random (non-fasting) blood glucose measurement of 140 mg/dL or less is considered normal, while a measurement of 200 mg/dL or more indicates diabetes.	After hospital discharge (up to 10 days)
Secondary	Percent of Time With BG Between 70-180 mg/dL After Discharge	Glycemic control after hospital discharge is measured by the percent of time with BG in the range of 70-180 mg/dL.	After hospital discharge (up to 10 days)
Secondary	Number of Clinically Significant Hypoglycemia Events After Discharge	The mean number of clinically significant hypoglycemia events, defined as BG <54 mg/dl (3.0mmol/L), during the day and night after hospital discharge, per participant is presented here.	After hospital discharge (up to 10 days)
Secondary	Number of Hypoglycemia Events After Discharge	The mean number of hypoglycemia events, defined as BG < 70 (<3.9 mmol/L), per participant after hospital discharge is presented here.	After hospital discharge (up to 10 days)
Secondary	Count of Participants With Hypoglycemia After Discharge	Hypoglycemia is defined as BG < 70 mg/dL (<3.9 mmol/L) and severe hypoglycemia is defined as BG < 54 mg/dL (<3.0 mmol/L).	After hospital discharge (up to 10 days)
Secondary	Percent of Time With Hyperglycemia After Discharge	The percentage of time above the desired BG range, during the day and night after hospital discharge was assessed.	After hospital discharge (up to 10 days)
Secondary	Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) After Discharge	Mean amplitude of glycemic excursions (MAGE), together with mean and standard deviation, is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one standard of mean glycemia. It is designed to assess major glucose swings and exclude minor ones	After hospital discharge (up to 10 days)